Search

Lake Cajititlan is an endorheic tropical lake located in the state of Jalisco, Mexico, which has suffered the consequences of high levels of eutrophication. This study assessed the presence of heavy metals and metalloids in Lake Cajititlan to ascertain possible risks to its aquatic biota and the environment. Eleven monitoring sites were selected throughout the lake; from each site, one sample was taken from the sediments and another from the sediment-water interface by using an Ekman dredger and a Van Dorn bottle, respectively. The measured metals in each sample were As, Cd, Cr, Hg, Pb, Zn, Cu, Ni, Fe, Mn, and Al. The results showed the following sequence of heavy metal concentrations Al > Fe > Mn > Zn > Cu > Cr, wherein Al had the highest average concentration and Cr had the lowest. As, Cd, Hg, and Pb were practically undetectable. Because the predominant rock in the lake basin is volcanic tuff and the soil is vertisol, the high quantities of Al and Fe suggest the weathering of the basin’s minerals. The analyses of the sediment-water samples contained small amounts of dissolved Al, Fe, and Mn. According to the Hakanson equations with Hg, Cd, As, Cu, Pb, Cr, and Zn, the calculations of the contamination degree and ecological risk revealed that the presence of metals and metalloids does not present a potential risk to the aquatic biota; nonetheless, the water is not suitable for local human consumption due to an unrelated factor associated with nutrient and bacteriological contamination. The results show that heavy metals in the sediments were dispersed throughout the lake mostly because of the weathering of minerals from the local basin and not because of the punctual discharges of the pollutants from the municipal wastewater treatment plants (WWTPs). However, to ensure that the small amounts of dissolved metals (Al, Fe, and Mn) do not affect the aquatic biota, the fish species and phytoplankton need to be internally analyzed.

Pancreatic cancer is a malignancy of great impact in developed countries and is having an increasing impact in Latin America. Incidence and mortality rates are similar for this cancer. This is an important reason to offer to the patients the best treatments available. During the Latin American Symposium of Gastroenterology Oncology (SLAGO) held in Viña del Mar, Chile, in April 2015, a multidisciplinary group of specialists in the field met to discuss about this disease. The main conclusions of this meeting, where practitioners from most of Latin American countries participated, are listed in this consensus that seek to serve as a guide for better decision making for patients with pancreatic cancer in Latin America.

Lake Cajititlan is a shallow water body located in an endorheic basin in western Mexico at 1551 m a.s.l. The surface area is 1744 ha, maximum storage volume achieved is 70.89 Hm3, and maximum depth is 5.4 m at its maximum capacity. The lake has experienced significant changes in its level because of drought conditions in recent years. Because the lake has shallow features and is settled in a closed basin with rapid population growth, the lake water has suffered severe anthropogenic contamination causing damages in its intrinsic esthetic, social, environmental, and economic values.

Pancreatic cancer is a malignancy of great impact in developed countries and is having an increasing impact in Latin America. Incidence and mortality rates are similar for this cancer. This is an important reason to offer to the patients the best treatments available. During the Latin American Symposium of Gastroenterology Oncology (SLAGO) held in Vina del Mar, Chile, in April 2015, a multidisciplinary group of specialists in the field met to discuss about this disease. The main conclusions of this meeting, where practitioners from most of Latin American countries participated, are listed in this consensus that seek to serve as a guide for better decision making for patients with pancreatic cancer in Latin America.

Purpose : To provide recommendations for the implementation of high dose rate (HDR) 192 Ir brachytherapy technology in developing countries. Methods : An Advisory Group Meeting of the International Atomic Energy Agency (IAEA) met to address the implementation of HDR 192 Ir brachytherapy technology in developing countries. These recommendations reflect only the personal opinions of the authors and do not necessarily represent the opinion of the IAEA. Results : An HDR treatment system should be purchased as a complete unit that includes the 192 Ir radioactive source, source loading unit, applicators, treatment planning system, and control console. Infrastructure support may require additional or improved buildings and procurement of or access to new imaging facilities. A supportive budget is needed for quarterly source replacement and the annual maintenance necessary to keep the system operational. The radiation oncologist, medical physicist, and technologist should be specially trained before HDR can be introduced. Training for the oncologist and medical physicist is an ongoing process as new techniques or sites of treatment are introduced. Procedures for quality assurance (QA) of patient treatment, and the planning system must be introduced. Emergency procedures with adequate training of all associated personnel must be in place. Conclusions : The decision to select HDR in preference to alternate methods of brachytherapy is influenced by the ability of the machine to treat a wide variety of clinical sites. In departments with personnel and budgetary resources to support this equipment appropriately, economic advantage becomes evident only if large numbers of patients are treated. Intangible benefits of source safety, personnel safety, and easy adaptation to fluctuating demand for treatments also require consideration when evaluating the need to introduce this treatment system.

[1] Valentini V, Bourhis J, Hollywood D. ESTRO 2012 strategy meeting: vision for Radiation Oncology. Radiother Oncol 2012;103:99–102. [2] Potter R, Eriksen JG, Beavis AW, Coffey M, Verfaillie C, Leer JW, et al. Competencies in Radiation Oncology: a new approach for education and training of professionals for Radiotherapy and Oncology in Europe. Radiother Oncol 2012;103:1–4. [3] Urbanski B. The future of Radiation Oncology: considerations of young medical doctor. Rep Pract Oncol Radiother 2012;17:288–93. [4] Boyle FM, Robinson E, Dunn SM, Heinrich PC. Multidisciplinary care in cancer: the fellowship of the ring. JCO 2005 Feb 1;23:916–20. [5] Leer JWH. The future development of Radiation Oncology in Europe: a personal view. Radiother Oncol 2011;100:7–9. [6] Baumann M, Zips D, Appold S. Radiotherapy of lung cancer: technology meets biology meets multidisciplinarity. Radiother Oncol 2009;91:279–81. [7] Ramos A, Torrecilla JL, Lara P, Herruzo I, Contreras J, Manas A, et al. Should the prescription of oral anticancer drugs be restricted? Rep Pract Oncol Radiother 2012;17:187–9. [8] Van Tol-Geerdink JJ, Leer JW, Van Lin ENJT, Schimmel EC, Huizenga H, Van Daal WAJ, et al. Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being. Int J Radiat Oncol Biol Phys 2008;70:442–8. [9] Colomer R, Alba E, Gonzalez-Martin A, Paz-Ares L. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol 2010;21:195–8. [10] Guedea F, Macia M, Sanchez Calzado JA, Ramos A, Lopez Torrecilla JL, Herruzo I, et al. Treatment of cancer with drugs: a controversy. Ann Oncol 2011;22: 747–8. [11] Linares L, Poitevin A, De la Pena C, Britton KR, Ospino R, Lara R, et al. The prescription of oral anticancer drugs: another perspective. Rep Pract Oncol Radiother 2012 [Internet] [cited 2012 Nov 21]. Available from: http:// www.sciencedirect.com/science/article/pii/S1507136712001587. [12] Janaszczyk A, Bogusz-Czerniewicz M. Comparison of curricula in radiation technology in the field of radiotherapy in selected European Union countries. Rep Pract Oncol Radiother 2011;16:189–97.